Hetero became first Indian company to receive DGCI’s approval for hepatitis C drug

Dec 9, 2015 12:44 IST

Hyderabad-based Hetero Drugs on 8 December 2015 announced that it received the approval of Drug Controller General of India (DCGI) to launch fixed-dose combination therapy Ledipasvir-Sofosbuvir. The product will be available under the brand name Ledisof in India.

With this approval, Hetero became the first company in the country to get approval from DGCI to launch hepatitis C medicines.

In September 2014, Hetero signed a non-exclusive licensing agreement with the USA-based Gilead Sciences in to manufacture and market chronic hepatitis C medicines.

This fixed-dose combination is the generic version of Gilead’s brand Harvoni. It was approved by US FDA for the treatment of chronic hepatitis genotype 1 in both treatment –naïve and treatment-experienced patients.

And, Sofosbuvir in combination with Ledipasvir has shown to have high cure rates of around 90 percentage.

About Hepatitis C

• It is a growing public health concern, particularly in developing countries.
• In India alone, it is estimated that 12-18 million patients are infected with Hepatitis C which is several fold greater than those with HIV/AIDS.
• Untreated chronic hepatitis C increases the risk of cirrhosis of liver, liver failure and hepatocellular carcinoma.

Now get latest Current Affairs on mobile, Download # 1  Current Affairs App

Is this article important for exams ? Yes9 People Agreed
Read more Current Affairs on: Hetero , hepatitis C , DGCI , Ledisof , Indian drug company

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK